Navigation Links
Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance
Date:12/10/2007

ALLEGAN, Mich., Dec. 10 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole delayed-release tablets. As the exclusive marketer and distributor of this product for the store brand over-the-counter (OTC) market in the United States, Perrigo expects to begin shipping its product during the first quarter of calendar year 2008, with full year annual sales to be in the range of $150 - $200 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "The approval from the FDA is the final regulatory step for this exclusive product launch, which we expect to be the largest product in Perrigo's 120 year history. While we are excited about the opportunity, we will obviously continue investing in research and development to add more new products to our product offering. The launch of Omeprazole is another example of Perrigo's dedication to make quality healthcare more affordable."

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between $0.20 and $0.25 earnings per share in fiscal year 2008. As a result of the Omeprazole launch, full year earnings for fiscal year 2008 are expected to be in the range of $1.32 to $1.47 per share.

Prilosec OTC(R) is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately $750 million in all outlets.

Headquartered in Or Akiva, Israel, Dexcel Pharma Technologies, Ltd. is a privately-held, international specialty pharmaceutical company which focuses on the development, manufacture and marketing of innovative prescription, generic prescription, and OTC
'/>"/>

SOURCE The Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... BEIJING , July 24, 2015 Origin Agritech ... supplier of crop seeds in China , ... third quarter fiscal year 2015 ended June 30, 2015, before ... The Company will host a teleconference on August 5th, 2015, ... time to discuss the results. To participate in ...
(Date:7/24/2015)... 2015 , Adds integrated small ... product offering for chronic kidney disease and oncology patients ... complications and dermatology , Increases group revenue and ... ,the Company"), a leading China -based ... biopharmaceutical products, today announced that it has acquired the ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , ... July 23, 2015 , ... Science and technology ... to new drug therapies and devices – according to Susan Chang, MD, director of ... session on how science and new technology are impacting the development of new treatments ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... PCT ... , ... July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment ... of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of ...
... assistant professor of engineering, has been named one of ... for Scientists and Engineers. The White House named the ... award recognizes outstanding scientists and engineers who, early in ... frontiers of knowledge. It is the highest honor bestowed ...
... , Inc. ("Senesco" or the "Company") (NYSE Amex: ... Company entered into a definitive purchase agreement with Partlet Holdings Ltd. ... of its common stock (the "Shares") at a price of $0.90 ... 1,000,000 shares of common stock, which warrants are exercisable immediately at ...
Cached Biology Technology:Progenitor Cell Therapy Appoints VP of Manufacturing Operations 2Progenitor Cell Therapy Appoints VP of Manufacturing Operations 3Brown engineering professor wins prestigious White House award 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... in This Edition: , , New hope for tapping vast ... step closer to use in the U. S. , Toward ... , Key proteins identified in the quest for male contraceptive, ... Journalists, Resources: , Press releases, chat room sessions, ...
... today that it has increased its support of high-impact ... Awards to 47 scientists, many of whom are in ... to be up to $138 million over five years, ... transform biomedical and behavioral science. "Nothing is ...
... gut bacteria are thought to be involved in colon cancer ... the USA have discovered that a molecule produced by a ... cancer cells. The research, published in the October issue of ... the way gut bacteria can cause colon cancer. There ...
Cached Biology News:ACS PressPac -- Sept. 17, 2008 2ACS PressPac -- Sept. 17, 2008 3ACS PressPac -- Sept. 17, 2008 4ACS PressPac -- Sept. 17, 2008 5ACS PressPac -- Sept. 17, 2008 6ACS PressPac -- Sept. 17, 2008 7ACS PressPac -- Sept. 17, 2008 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 2NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 3NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 4NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 5NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 6NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 7NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 9Cancer-causing gut bacteria exposed 2
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
TRBP1 Antibody...
Request Info...
Biology Products: